TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Conditions: Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma Interventions: Biological: TBio-4101; Drug: Pembrolizumab; Drug: Platinum based chemotherapy; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Phase 1B of TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Conditions: Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma Interventions: Biological: TBio-4101; Drug: Pembrolizumab; Drug: Platinum based chemotherapy; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinomas; Resectable Head and Neck Squamous-cell Carcinoma Interventions: Drug: Tislelizumab; Drug: Nab-paclitaxel; Drug: Carboplatin Sponsors: Xiang Lu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Conditions: Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma of the Anus Interventions: Other: Multiparameter analysis of each sample Sponsors: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet
Conditions: Melanoma Stage Iv; Metastatic Melanoma Interventions: Behavioral: Mediterranean Diet Intervention Sponsors: University Hospital Rijeka Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Conditions: Solid Tumor, Adult Interventions: Drug: BH009 Sponsors: Zhuhai Beihai Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical Cancer
Conditions: Cervical Squamous Cell Carcinoma; Radiotherapy; Immunotherapy Interventions: Radiation: PLDR+Cardunizumab Sponsors: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Conditions: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer Interventions: Drug: Leflunomide; Drug: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab Sponsors: N.N. Petrov National Medical Research Center of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Skin Tumor Biomarkers by Mass Spectrometry Imaging
Conditions: Skin Cancer; Squamous Cell Carcinoma; Basal Cell Carcinoma; Non-melanoma Skin Cancer Interventions: Other: Biopsy Sponsors: Bispebjerg Hospital; University of Copenhagen Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Adebrelimab; Drug: Dalpiciclib 100mg; Drug: Dalpiciclib 150mg Sponsors: West China Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Conditions: Cutaneous Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma Interventions: Drug: Eutectic Mixture of Local Anesthetics; Drug: Placebo Administration; Other: Questionnaire Administration Sponsors: Ohio State University Comprehensive Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Conditions: Squamous Cell Carcinoma of the Head and Neck; Oropharynx; Human Papillomavirus Viruses; Drug Therapy; Cancer Vaccine Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: PRGN-2009 Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma
Conditions: Melanoma; Melanoma, Skin Sponsors: AI Labs Group S.L; Servicio Vasco de Salud Osakidetza, Spain; Osakidetza; Hospital de Basurto; Hospital de Cruces Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
Conditions: Efficacy and Safety Interventions: Drug: Envafolimab combined with chemotherapy Sponsors: Hairong Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Conditions: Melanoma Interventions: Biological: Vusolimogene oderparepvec (RP1) Sponsors: Yana Najjar; Replimune Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
